Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Shares of AEMD stock opened at $1.01 on Wednesday. Aethlon Medical has a 1 year low of $0.88 and a 1 year high of $6.22. The stock has a market cap of $15.56 million, a PE ratio of -1.70 and a beta of 0.79. The business’s fifty day moving average is $1.14 and its 200-day moving average is $1.45.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Aethlon Medical by 11.6% during the 1st quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock valued at $395,000 after purchasing an additional 28,097 shares during the period. NTB Financial Corp acquired a new position in shares of Aethlon Medical during the 4th quarter valued at $32,000. Finally, BlackRock Inc. increased its position in shares of Aethlon Medical by 771.7% during the 3rd quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock valued at $282,000 after purchasing an additional 64,691 shares during the period. Institutional investors own 10.58% of the company’s stock.

About Aethlon Medical (Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

See Also